These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 9528995)

  • 1. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models.
    Ke HZ; Paralkar VM; Grasser WA; Crawford DT; Qi H; Simmons HA; Pirie CM; Chidsey-Frink KL; Owen TA; Smock SL; Chen HK; Jee WS; Cameron KO; Rosati RL; Brown TA; Dasilva-Jardine P; Thompson DD
    Endocrinology; 1998 Apr; 139(4):2068-76. PubMed ID: 9528995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
    Armamento-Villareal R; Sheikh S; Nawaz A; Napoli N; Mueller C; Halstead LR; Brodt MD; Silva MJ; Galbiati E; Caruso PL; Civelli M; Civitelli R
    J Bone Miner Res; 2005 Dec; 20(12):2178-88. PubMed ID: 16294271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats.
    Ke HZ; Qi H; Chidsey-Frink KL; Crawford DT; Thompson DD
    J Bone Miner Res; 2001 Apr; 16(4):765-73. PubMed ID: 11316005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.
    Nuttall ME; Bradbeer JN; Stroup GB; Nadeau DP; Hoffman SJ; Zhao H; Rehm S; Gowen M
    Endocrinology; 1998 Dec; 139(12):5224-34. PubMed ID: 9832463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.
    Ke HZ; Simmons HA; Pirie CM; Crawford DT; Thompson DD
    Endocrinology; 1995 Jun; 136(6):2435-41. PubMed ID: 7750465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat.
    Ke HZ; Qi H; Crawford DT; Chidsey-Frink KL; Simmons HA; Thompson DD
    Endocrinology; 2000 Apr; 141(4):1338-44. PubMed ID: 10746637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 3-phenyl-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- 2H-1-benzopyran-7-ol (CHF 4056), a novel nonsteroidal estrogen agonist/antagonist, on reproductive and nonreproductive tissue.
    Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
    J Pharmacol Exp Ther; 2002 Mar; 300(3):802-9. PubMed ID: 11861784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model.
    Ke HZ; Chen HK; Simmons HA; Qi H; Crawford DT; Pirie CM; Chidsey-Frink KL; Ma YF; Jee WS; Thompson DD
    Bone; 1997 Jan; 20(1):31-9. PubMed ID: 8988345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
    Qu Q; Zheng H; Dahllund J; Laine A; Cockcroft N; Peng Z; Koskinen M; Hemminki K; Kangas L; Väänänen K; Härkönen P
    Endocrinology; 2000 Feb; 141(2):809-20. PubMed ID: 10650964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.
    Sato M; Turner CH; Wang T; Adrian MD; Rowley E; Bryant HU
    J Pharmacol Exp Ther; 1998 Oct; 287(1):1-7. PubMed ID: 9765314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidences for antiosteoporotic and selective estrogen receptor modulator activity of silymarin compared with ethinylestradiol in ovariectomized rats.
    El-Shitany NA; Hegazy S; El-Desoky K
    Phytomedicine; 2010 Feb; 17(2):116-25. PubMed ID: 19577454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of raloxifene on tibia histomorphometry in ovariectomized rats.
    Evans G; Bryant HU; Magee D; Sato M; Turner RT
    Endocrinology; 1994 May; 134(5):2283-8. PubMed ID: 8156931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.
    Ke HZ; Chen HK; Qi H; Pirie CM; Simmons HA; Ma YF; Jee WS; Thompson DD
    Bone; 1995 Nov; 17(5):491-6. PubMed ID: 8579962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.
    Rosati RL; Da Silva Jardine P; Cameron KO; Thompson DD; Ke HZ; Toler SM; Brown TA; Pan LC; Ebbinghaus CF; Reinhold AR; Elliott NC; Newhouse BN; Tjoa CM; Sweetnam PM; Cole MJ; Arriola MW; Gauthier JW; Crawford DT; Nickerson DF; Pirie CM; Qi H; Simmons HA; Tkalcevic GT
    J Med Chem; 1998 Jul; 41(16):2928-31. PubMed ID: 9685230
    [No Abstract]   [Full Text] [Related]  

  • 15. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
    Black LJ; Sato M; Rowley ER; Magee DE; Bekele A; Williams DC; Cullinan GJ; Bendele R; Kauffman RF; Bensch WR
    J Clin Invest; 1994 Jan; 93(1):63-9. PubMed ID: 8282823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats.
    Ke HZ; Foley GL; Simmons HA; Shen V; Thompson DD
    Endocrinology; 2004 Apr; 145(4):1996-2005. PubMed ID: 14726439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia.
    Sibonga JD; Dobnig H; Harden RM; Turner RT
    Endocrinology; 1998 Sep; 139(9):3736-42. PubMed ID: 9724025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats.
    Goss PE; Qi S; Cheung AM; Hu H; Mendes M; Pritzker KP
    J Steroid Biochem Mol Biol; 2004 Sep; 92(1-2):79-87. PubMed ID: 15544933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
    Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
    J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.
    Sutherland MK; Brady H; Gayo-Fung LM; Leisten J; Lipps SG; McKie JA; O'Leary E; Patnaik N; Anderson DW; Bhagwat SS; Stein B
    Calcif Tissue Int; 2003 Jun; 72(6):710-6. PubMed ID: 14563000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.